1
|
Lahiri S. Editorial: Production of novel medical radionuclides and innovative radiopharmaceuticals. Front Chem 2024; 12:1386045. [PMID: 38476654 PMCID: PMC10927950 DOI: 10.3389/fchem.2024.1386045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2024] [Accepted: 02/19/2024] [Indexed: 03/14/2024] Open
Affiliation(s)
- Susanta Lahiri
- Department of Chemistry, Diamond Harbour Women’s University, Sarisha, India
- Department of Physics, Sidho Kanho Birsha University, Purulia, India
| |
Collapse
|
2
|
Sciacca G, Martini P, Cisternino S, Mou L, Amico J, Esposito J, Gorgoni G, Cazzola E. A Universal Cassette-Based System for the Dissolution of Solid Targets. Molecules 2021; 26:molecules26206255. [PMID: 34684836 PMCID: PMC8539783 DOI: 10.3390/molecules26206255] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2021] [Revised: 10/13/2021] [Accepted: 10/14/2021] [Indexed: 11/16/2022] Open
Abstract
Cyclotron-based radionuclides production by using solid targets has become important in the last years due to the growing demand of radiometals, e.g., 68Ga, 89Zr, 43/47Sc, and 52/54Mn. This shifted the focus on solid target management, where the first fundamental step of the radiochemical processing is the target dissolution. Currently, this step is generally performed with commercial or home-made modules separated from the following purification/radiolabelling modules. The aim of this work is the realization of a flexible solid target dissolution system to be easily installed on commercial cassette-based synthesis modules. This would offer a complete target processing and radiopharmaceutical synthesis performable in a single module continuously. The presented solid target dissolution system concept relies on an open-bottomed vial positioned upon a target coin. In particular, the idea is to use the movement mechanism of a syringe pump to position the vial up and down on the target, and to exploit the heater/cooler reactor of the module as a target holder. All the steps can be remotely controlled and are incorporated in the cassette manifold together with the purification and radiolabelling steps. The performance of the device was tested by processing three different irradiated targets under different dissolution conditions.
Collapse
Affiliation(s)
- Gabriele Sciacca
- Legnaro National Laboratories, National Institute for Nuclear Physics, 35020 Legnaro, Italy; (S.C.); (L.M.); (J.E.)
- Department of Industrial Engineering, University of Padova, 35131 Padova, Italy
- Correspondence:
| | - Petra Martini
- Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy;
| | - Sara Cisternino
- Legnaro National Laboratories, National Institute for Nuclear Physics, 35020 Legnaro, Italy; (S.C.); (L.M.); (J.E.)
- Department of Industrial Engineering, University of Padova, 35131 Padova, Italy
| | - Liliana Mou
- Legnaro National Laboratories, National Institute for Nuclear Physics, 35020 Legnaro, Italy; (S.C.); (L.M.); (J.E.)
| | - Jonathan Amico
- Cyclotron & Radiopharmacy Department, Sacro Cuore Hospital, 37024 Negrar, Italy; (J.A.); (G.G.); (E.C.)
| | - Juan Esposito
- Legnaro National Laboratories, National Institute for Nuclear Physics, 35020 Legnaro, Italy; (S.C.); (L.M.); (J.E.)
| | - Giancarlo Gorgoni
- Cyclotron & Radiopharmacy Department, Sacro Cuore Hospital, 37024 Negrar, Italy; (J.A.); (G.G.); (E.C.)
| | - Emiliano Cazzola
- Cyclotron & Radiopharmacy Department, Sacro Cuore Hospital, 37024 Negrar, Italy; (J.A.); (G.G.); (E.C.)
| |
Collapse
|
3
|
Reissig F, Bauer D, Ullrich M, Kreller M, Pietzsch J, Mamat C, Kopka K, Pietzsch HJ, Walther M. Recent Insights in Barium-131 as a Diagnostic Match for Radium-223: Cyclotron Production, Separation, Radiolabeling, and Imaging. Pharmaceuticals (Basel) 2020; 13:E272. [PMID: 32992909 PMCID: PMC7599757 DOI: 10.3390/ph13100272] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2020] [Revised: 09/21/2020] [Accepted: 09/22/2020] [Indexed: 12/17/2022] Open
Abstract
Barium-131 is a single photon emission computed tomography (SPECT)-compatible radionuclide for nuclear medicine and a promising diagnostic match for radium-223/-224. Herein, we report on the sufficient production route 133Cs(p,3n)131Ba by using 27.5 MeV proton beams. An average of 190 MBq barium-131 per irradiation was obtained. The SR Resin-based purification process led to barium-131 in high radiochemical purity. An isotopic impurity of 0.01% barium-133 was detectable. For the first time, radiolabeling of the ligand macropa with barium-131 was performed. Radiolabeling methods under mild conditions and reaction controls based on TLC systems were successfully applied. Small animal SPECT/ computed tomography (CT) measurements and biodistribution studies were performed using [131Ba]Ba(NO3)2 as reference and 131Ba-labeled macropa in healthy mice for the first time. Biodistribution studies revealed the expected rapid bone uptake of [131Ba]Ba2+, whereas 131Ba-labeled macropa showed a fast clearance from the blood, thereby showing a significantly (p < 0.001) lower accumulation in the bone. We conclude that barium-131 is a promising SPECT radionuclide and delivers appropriate imaging qualities in small animals. Furthermore, the relative stability of the 131Ba-labeled macropa complex in vivo forms the basis for the development of sufficient new chelators, especially for radium isotopes. Thereby, barium-131 will attain its goal as a diagnostic match to the alpha emitters radium-223 and radium-224.
Collapse
Affiliation(s)
- Falco Reissig
- Helmholtz-Zentrum Dresden-Rossendorf, Institut für Radiopharmazeutische Krebsforschung, Bautzner Landstraße 400, D-01328 Dresden, Germany; (F.R.); (D.B.); (M.U.); (M.K.); (K.K.); (H.-J.P.); (M.W.)
- Fakultät Chemie und Lebensmittelchemie, Technische Universität Dresden, D-01062 Dresden, Germany
| | - David Bauer
- Helmholtz-Zentrum Dresden-Rossendorf, Institut für Radiopharmazeutische Krebsforschung, Bautzner Landstraße 400, D-01328 Dresden, Germany; (F.R.); (D.B.); (M.U.); (M.K.); (K.K.); (H.-J.P.); (M.W.)
- Fakultät Chemie und Lebensmittelchemie, Technische Universität Dresden, D-01062 Dresden, Germany
| | - Martin Ullrich
- Helmholtz-Zentrum Dresden-Rossendorf, Institut für Radiopharmazeutische Krebsforschung, Bautzner Landstraße 400, D-01328 Dresden, Germany; (F.R.); (D.B.); (M.U.); (M.K.); (K.K.); (H.-J.P.); (M.W.)
| | - Martin Kreller
- Helmholtz-Zentrum Dresden-Rossendorf, Institut für Radiopharmazeutische Krebsforschung, Bautzner Landstraße 400, D-01328 Dresden, Germany; (F.R.); (D.B.); (M.U.); (M.K.); (K.K.); (H.-J.P.); (M.W.)
| | - Jens Pietzsch
- Helmholtz-Zentrum Dresden-Rossendorf, Institut für Radiopharmazeutische Krebsforschung, Bautzner Landstraße 400, D-01328 Dresden, Germany; (F.R.); (D.B.); (M.U.); (M.K.); (K.K.); (H.-J.P.); (M.W.)
- Fakultät Chemie und Lebensmittelchemie, Technische Universität Dresden, D-01062 Dresden, Germany
| | - Constantin Mamat
- Helmholtz-Zentrum Dresden-Rossendorf, Institut für Radiopharmazeutische Krebsforschung, Bautzner Landstraße 400, D-01328 Dresden, Germany; (F.R.); (D.B.); (M.U.); (M.K.); (K.K.); (H.-J.P.); (M.W.)
- Fakultät Chemie und Lebensmittelchemie, Technische Universität Dresden, D-01062 Dresden, Germany
| | - Klaus Kopka
- Helmholtz-Zentrum Dresden-Rossendorf, Institut für Radiopharmazeutische Krebsforschung, Bautzner Landstraße 400, D-01328 Dresden, Germany; (F.R.); (D.B.); (M.U.); (M.K.); (K.K.); (H.-J.P.); (M.W.)
- Fakultät Chemie und Lebensmittelchemie, Technische Universität Dresden, D-01062 Dresden, Germany
| | - Hans-Jürgen Pietzsch
- Helmholtz-Zentrum Dresden-Rossendorf, Institut für Radiopharmazeutische Krebsforschung, Bautzner Landstraße 400, D-01328 Dresden, Germany; (F.R.); (D.B.); (M.U.); (M.K.); (K.K.); (H.-J.P.); (M.W.)
| | - Martin Walther
- Helmholtz-Zentrum Dresden-Rossendorf, Institut für Radiopharmazeutische Krebsforschung, Bautzner Landstraße 400, D-01328 Dresden, Germany; (F.R.); (D.B.); (M.U.); (M.K.); (K.K.); (H.-J.P.); (M.W.)
| |
Collapse
|